
<DOC>
<DOCNO>WT02-B19-2</DOCNO>
<DOCOLDNO>IA092-000988-B014-236</DOCOLDNO>
<DOCHDR>
http://www.cytrx.com:80/prpatent.htm 206.216.36.35 19970110093751 text/html 6475
HTTP/1.0 200 OK
Date: Friday, 10-Jan-97 09:40:36 GMT
Server: WebSite/1.1
Allow-ranges: bytes
Accept-ranges: bytes
Content-type: text/html
Last-modified: Friday, 03-Jan-97 17:16:36 GMT
Content-length: 6260
</DOCHDR>
<HTML>

<HEAD>

<TITLE>FOR IMMEDIATE RELEASE</TITLE>

<META NAME="GENERATOR" CONTENT="Internet Assistant for Microsoft Word 2.0z">
</HEAD>



<BODY background=/icons/wrich/bg.gif>

<table width=95%><tr>
<td align=left>	
	<img src=/icons/cytrx.48pt.gif>
	</td>
<td align=right>
	<img src=/icons/multiopp.gif>
	</td>
</tr></table>
<img src=/icons/wrich/redline.gif>

<P>


<P>
<B><FONT SIZE=4>CYTRX CORPORATION ANNOUNCES 1996<B> SIX MONTH
RESULTS<BR>
</B></FONT></B>
<P>
<B>Atlanta, Georgia, July 24, 1996</B> <BR>

<P>
CytRx Corporation (NASDAQ: CYTR) today announced a net loss of
$1.1 million ($.15 per share) for the three months ended June
30, 1996 versus a loss of $3.3 million ($.42 per share) reported
in 1995.  For the six months ended June 30, 1996 the company reported
a net loss of $2.5 million ($.31 per share) versus $6.7 million
($.85 per share) in 1995.  As of June 30, 1996 CytRx had cash
and short-term investments of $22.2 million.<BR>

<P>
Jack J. Luchese, CytRx president and chief executive officer,
commented, “During the second quarter of 1996 CytRx continued
to move forward with development of RheothRx&reg;<I><SUB>pf</SUB></I>,
a new, purified form of RheothRx developed by CytRx which removes
impurities previously associated with renal side effects.  Last
month CytRx was awarded a composition of matter patent on this
improved compound which will provide patent protection through
2013.  Recent meetings with the FDA on RheothRx<I><SUB>pf</SUB></I>
were encouraging enough for us to accelerate our development plans
in order to commence advanced human clinical trials by early 1997
to study RheothRx<I><SUB>pf  </SUB></I>as a treatment for the
acute crisis of sickle cell disease.”<BR>

<P>
CytRx Corporation and its subsidiaries are engaged in the development
of pharmaceutical products.  CytRx Therapeutics is developing
RheothRx<I><SUB>pf</SUB></I> for the treatment of acute sickle
cell crisis and other vascular diseases.  CytRx's Vaxcel subsidiary
is developing the Optivax vaccine delivery system. Vetlife is
developing products to enhance food animal growth.  Proceutics
provides high quality preclinical development services to the
pharmaceutical industry.<BR>
<BR>
<BR>

<P>
<CENTER>CytRx Corporation and Subsidiaries<BR>
Condensed and Consolidated Statements Operations<BR>
(Amounts in Thousands except Per Share Data) <BR>
</CENTER>
<P>
<CENTER><TABLE CELLPADDING=2 CELLSPACING=6 BORDER=0>
<TR>
<TD></TD>
   <TD ALIGN=center COLSPAN=2><B>Three Months Ended<BR>June 30</B><HR>
</TD> 
   <TD ALIGN=center COLSPAN=2><B>Six Months Ended<BR>June 30</B><HR>
</TD>
<TR ALIGN="right">
   <TD></TD>
   <TD><B>1996</B></TD>
   <TD><B>1995</B></TD>
   <TD><B>1996 </B></TD>
   <TD><B>1995</B></TD>
<TR>
   <TD><B>Net Revenues</B></TD>
   <TD ALIGN=right>$862</TD>
   <TD ALIGN=right>$576</TD>
   <TD ALIGN=right>$1,521</TD>
   <TD ALIGN=right>1,239</TD>
<TR>
   <TD><B>Cost of Sales</B></TD>
   <TD ALIGN=right>(367)</TD>
   <TD ALIGN=right>(11)</TD>
   <TD ALIGN=right>(480)</TD>
   <TD ALIGN=right>(22)</TD>
<TR>
   <TD><B>Research and Development</B></TD>
   <TD ALIGN=right>(553)</TD>
   <TD ALIGN=right>(1,894)</TD>
   <TD ALIGN=right>(1,540)</TD>
   <TD ALIGN=right>(3,574)</TD>
<TR>
   <TD><B>Selling, General &amp; Administrative</B></TD>
   <TD ALIGN=right>(1,087)</TD>
   <TD ALIGN=right>(2,017)*</TD>
   <TD ALIGN=right>(1,958)</TD>
   <TD ALIGN=right>(4,361)*</TD>
<TR ALIGN="right">
   <TD></TD>
   <TD>-------</TD>
   <TD>-------</TD>
   <TD>-------</TD>
   <TD>-------</TD>
<TR>
   <TD><B>Net Loss</B></TD>
   <TD ALIGN=right>$(1,145)</TD>
   <TD ALIGN=right>$(3,346)</TD>
   <TD ALIGN=right>$(2,457)</TD>
   <TD ALIGN=right>$(6,718)</TD>
<TR>
   <TD><B>Net Loss per Common Share</B></TD>
   <TD ALIGN=right>$(.15)</TD>
   <TD ALIGN=right>$(.42)</TD>
   <TD ALIGN=right>$(.31)</TD>
   <TD ALIGN=right>$(.85)</TD>
<TR>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TR>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TR>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TR>
   <TD><B>Summary of Net Loss by Corporate Entity: </B></TD>
   <TD></TD>
   <TD></TD>
   <TD></TD>
   <TD></TD>
<TR>
   <TD><B>CytRx Corporation </B></TD>
   <TD ALIGN=right> $(694)</TD>
   <TD ALIGN=right>$(2,673)</TD>
   <TD ALIGN=right>$(1,055)</TD>
   <TD ALIGN=right>$(5,389)</TD>
<TR>
   <TD><B>Proceutics, Inc.</B></TD>
   <TD ALIGN=right>(150)</TD>
   <TD ALIGN=right>-</TD>
   <TD ALIGN=right>(559)</TD>
   <TD ALIGN=right>-</TD>
<TR>
   <TD><B>Vaxcel, Inc. </B></TD>
   <TD ALIGN=right> (217)</TD>
   <TD ALIGN=right>(518)</TD>
   <TD ALIGN=right>(513)</TD>
   <TD ALIGN=right>(892)</TD>
<TR>
   <TD><B>Vetlife, Inc. </B></TD>
   <TD ALIGN=right>(84)</TD>
   <TD ALIGN=right>(155)</TD>
   <TD ALIGN=right>(330)</TD>
   <TD ALIGN=right>(437)</TD>
<TR>
   <TD> </TD>
   <TD ALIGN=right>-------- </TD>
  <TD ALIGN=right>--------</TD>
   <TD ALIGN=right>--------</TD>
   <TD ALIGN=right>--------</TD>
<TR>
   <TD><B>Net Loss </B></TD>
   <TD ALIGN=right> $(1,145)</TD>
   <TD ALIGN=right>$(3,346)</TD>
   <TD ALIGN=right>$(2,457)</TD>
   <TD ALIGN=right>$(6,718)</TD>
<TR>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TR>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TR>
<TD><B>Cash and Short-term Investments</B></TD>
<TD ALIGN=right> $22,212</TD>
<TD ALIGN=right> $28,623</TD>
<TD></TD>
<TR>
<TD><B>Common Shares Outstanding</B></TD>
<TD ALIGN=right> 7,861</TD>
<TD ALIGN=right> 7,903</TD>
<TD></TD>
</TABLE>
</CENTER>

<P>
* Includes $992 and $1,103 for the three and six month periods,
respectively, of realized investment losses previously reflected
on the balance sheet as of December 31, 1994.  The six month period
also includes $1,395 related to a change in the method of accounting
for patent costs.
<BR>
<P>


<img src="/icons/rain_line.gif">	
<p>
<b>
[ <a href="/index.html">Home</a> 
| <a href="http://www.titermax.com">TiterMax</a> 
| <a href="/financial/overview.html">Investor Info</a> 
| <a href="/communications.html">Communications</a> 
| <a href="/adproceu.html">Proceutics</a>  
] </b>
<p>
</BODY>

</HTML>


</DOC>